Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics:

• Introduction (0:00)
• Overview of Prostate Cancer (3:00)
• Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12)
• Potential Role of Capivasertib in Metastatic HSPC (27:22)
• Current and Potential Future Role of PARP Inhibitors in Metastatic PC (46:39)
• Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic PC (1:09:14)

CME information and select publications

Featuring perspectives from Ms Caroline Kuhlman, Dr Eileen M O'Reilly, Dr Philip A Philip and Ms Amanda K Wagner, moderated by Dr O'Reilly, including the following topics:

• Introduction (0:00)
• Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD) (3:29)
• Recent Advances in Up-Front Treatment for Metastatic PAD (15:47)
• Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (39:58)
• Novel Strategies Targeting RAS Mutations in Advanced PAD (48:20)
• Utility of Tumor Treating Fields in PAD Management (1:13:58)

CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:

• Introduction (0:00)
• Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
• Practical Considerations with Oral SERDs (15:43)
• Potential Role of Combination Approaches with Oral SERDs (26:33)
• Gastrointestinal Adverse Events Documented with Oral SERDs (38:19)
• Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:54)
• Other Class-Effect Toxicities Associated with Oral SERDs (1:00:56)
• Emerging Utility of Adjuvant Oral SERDs (1:10:20)
• Unique Toxicities Associated with 1 or More Oral SERDs (1:19:22)

CME information and select publications

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:

• Introduction (00:00)
• Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)
• Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)
• Strategies to Prevent and Manage Hyperglycemia (27:02)
• Clinical Utility of Capivasertib for HR-Positive mBC (38:09)
• Mitigation and Management of Gastrointestinal Adverse Events (51:05)
• Management of Dermatologic Adverse Events (59:58)
• Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42)
• Monitoring and Management of Cytopenias (1:21:23)

CME information and select publications

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:

• Introduction (00:00)
• Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)
• Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)
• Utility of Belantamab Mafodotin in R/R MM (49:29)
• Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)

CME information and select publications

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:

• Introduction (00:00)
• Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)
• Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52)
• Adjuvant CDK4/6 Inhibitor Therapy (17:14)
• Practical Considerations with CDK4/6 Inhibitors (29:57)
• Monitoring and Management of Cytopenias (42:02)
• CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32)
• Management of Gastrointestinal Adverse Events (1:03:47)
• CDK4/6 Inhibitors in Unique Populations (1:10:41)
• Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48)

CME information and select publications

Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics:

• Introduction (00:00)
• Overview of Ovarian Cancer (OC) (2:12)
• Role of PARP Inhibitors in Advanced OC (4:56)
• Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)
• Role of Relacorilant in Advanced OC (57:08)
• Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12)

NCPD information and select publications

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:

• Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)
• Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)
• Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)
• Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)
• Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)
• Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)
• Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30)

CME information and select publications